-
-
-
-
-
-
-
-
-
-
GSK Gains Ground in COPD Market with Nucala
GSK
GSK’s Nucala has received FDA approval as an add-on treatment for eosinophilic COPD, positioning it against Dupixent. Backed by strong trial results, GSK targets $669M in peak annual sales for the new indication.
疏附县|
金寨县|
隆化县|
平遥县|
本溪|
龙州县|
石台县|
通辽市|
白朗县|
上蔡县|
阳高县|
澄城县|
武城县|
积石山|
金沙县|
资阳市|
太仆寺旗|
天水市|
保康县|
民和|
宜城市|
吉木萨尔县|
峨山|
通许县|
格尔木市|
洛宁县|
遵义市|
东丽区|
阳谷县|
洛扎县|
卢龙县|
吉安市|
富顺县|
连山|
潍坊市|
安龙县|
文安县|
定远县|
昌吉市|
深泽县|
桐乡市|